Curis is focused on anti-cancer research, aiming to create innovative, first-in-class therapeutic agents for the treatment of various cancers. We’ll start with Curis, a small-cap biotech with both an approved drug on the market and an active development pipeline. We’ve take a first step, using the TipRanks platform to look up a pair of small-cap stocks with low share price and a high upside – in fact, according to Raymond James analyst Dane Leone both of them are likely to double or better in the coming year.
But high returns are out there, and the biggest ‘trick’ for an investor to learn is where to find that high potential. Not every stock is going to turn into the next tech giant, of course.
Long-term appreciation has worked its magic. Apple, with a current market cap well north of $2 trillion, was a plucky little small-cap with a share price of $1.10 back in the late 1980s, and Amazon, with its famously high 4-digit share price, sold for less than $10 per share 20 years ago. Some of today’s tech giants are prime examples of the phenomenon. A small cap stock, one with a market value lower than $2 billion, will usually feature a relatively low share price – and when share price is low, even a small gain in absolute terms will quickly translate into a high-percentage return. It’s the basic arithmetic behind finding a solid return potential. The two attributes are related, and frequently offer investors a fine combination of risk-reward ratio to emphasize the former. Let’s talk a bit about return potential, and small-cap stocks.
0 kommentar(er)
